Roche and Zealand Pharma Partner to Advance Obesity Treatment

Roche has entered into an exclusive collaboration with Zealand Pharma to co-develop and co-commercialize petrelintide, a promising amylin analog for obesity treatment. Petrelintide, currently in Phase 2 trials, is designed as a once-weekly subcutaneous therapy with the potential for improved tolerability over existing weight management treatments. As part of the agreement, Roche will also explore a fixed-dose combination of petrelintide with its lead incretin asset, CT-388, to enhance efficacy and patient outcomes.

Leaders from both companies expressed optimism about the partnership’s potential impact on obesity care. Roche Pharmaceuticals CEO Teresa Graham emphasized their shared vision for petrelintide as a foundational therapy, leveraging Roche’s expertise in cardiovascular and metabolic diseases. Zealand Pharma CEO Adam Steensberg highlighted the collaboration as a transformative step for obesity management, positioning Zealand Pharma as a key player in the field. With this alliance, both companies aim to set new standards for effective and sustainable weight management solutions.